Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.39 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448063 | 1.00 | MEN1 (0.39) | MEN1KMT2AIDO1HIF1AHPGD | |
| SCHEMBL80688 | 0.88 | SIRT2 (0.39) | MEN1KMT2AIDO1HIF1AHPGD | |
| SCHEMBL29447991 | 0.85 | HTR2A (0.40) | KMT2AIDO1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3126933 | 0.85 | HTR2A (0.40) | KMT2AIDO1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19030709 | 0.84 | MEN1 (0.40) | MEN1KMT2AIDO1HIF1AHPGD | |
| SCHEMBL11539939 | 0.82 | IDO1 (0.41) | MEN1KMT2AIDO1HIF1AHPGD | |
| SCHEMBL30853201 | 0.82 | MEN1 (0.41) | MEN1KMT2AIDO1HIF1AHPGD | |
| SCHEMBL269490 | 0.82 | MEN1 (0.41) | MEN1KMT2AIDO1HIF1AHPGD | |
| SCHEMBL3620010 | 0.80 | TP53 (0.44) | MEN1KMT2AIDO1HIF1AHPGD | |
| SCHEMBL27830893 | 0.80 | DPP4 (0.43) | IDO1MPOPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-07 | — | — | US | disclosed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2020229968-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2020-11-19 | — | — | WO | disclosed |
| US-10259785-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| CN-102666545-A | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | CELLZOME LTD | 2012-09-12 | — | — | CN | disclosed |
| CN-100562516-C | Amyloid-beta produces and the excretory inhibitor | DAIICHI SEIYAKU CO (JP) | 2009-11-25 | — | — | CN | disclosed |
| CN-1326858-C | tricyclic spiropiperidine compounds | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | CN | disclosed |
| CN-1974574-A | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2007-06-06 | — | — | CN | disclosed |
| CN-1894232-A | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | disclosed |
| CN-1675218-A | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-09-28 | — | — | CN | disclosed |
| CN-1585746-A | Inhibitors of beta-amyloid production and secretion | DAIICHI SEIYAKU CO (JP) | 2005-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | MEN1 2340/4885KMT2A 3402/4885IDO1 2392/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | MEN1 3585/4885KMT2A 1488/4885IDO1 2074/4885 |
| US-10259785-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | MEN1 261/4885KMT2A 973/4885IDO1 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.